1. Home
  2. SDGR vs PCRX Comparison

SDGR vs PCRX Comparison

Compare SDGR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$15.03

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$25.59

Market Cap

999.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDGR
PCRX
Founded
1990
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
999.0M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
SDGR
PCRX
Price
$15.03
$25.59
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$21.00
$30.25
AVG Volume (30 Days)
1.4M
448.9K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
107.44
EPS
N/A
0.07
Revenue
$255,869,000.00
$541,533,000.00
Revenue This Year
$0.76
$6.78
Revenue Next Year
$4.60
$8.54
P/E Ratio
N/A
$368.29
Revenue Growth
23.29
26.04
52 Week Low
$10.95
$18.80
52 Week High
$23.02
$27.64

Technical Indicators

Market Signals
Indicator
SDGR
PCRX
Relative Strength Index (RSI) 42.66 57.63
Support Level $11.27 $21.89
Resistance Level $16.47 $26.94
Average True Range (ATR) 0.77 0.84
MACD -0.28 -0.04
Stochastic Oscillator 7.56 45.74

Price Performance

Historical Comparison
SDGR
PCRX

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: